Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia

Carregando...
Imagem de Miniatura
Citações na Scopus
42
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
DOVE MEDICAL PRESS LTD
Citação
CLINICAL INTERVENTIONS IN AGING, v.9, p.939-944, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Fibromyalgia and osteoarthritis may present a relationship with the -concentration of cytokines. The aim of this study was to compare the serum concentrations of IL-12p70, tumor necrosis factor, IL-10, IL-6, IL-1 beta, and IL-8 in patients with knee osteoarthritis and fibromyalgia. Materials and methods: The study included 53 women (71.2 +/- 7.6 years old) diagnosed with knee osteoarthritis with moderate-to-severe pain (visual analog scale. 4) for at least 3 months. Sixty women (54.1 +/- 8.1 years old) diagnosed with fibromyalgia according to the American College of Rheumatology criteria and with moderate-to-severe pain (visual analog scale. 4) also participated in this study. For the dosage of cytokines, blood was collected in the morning: 5 mL from the cubital vein. The material was centrifuged at 4 degrees C, separated into 100 mu L aliquots and stored at -80 degrees C until processing. Serum concentrations of the studied cytokines were assessed using the BD Cytometric Bead Array method. Data were analyzed with Student's t-test and the Mann-Whitney U test. Results: We found higher levels of IL-6, IL-10, and IL-1 beta in fibromyalgia patients. After adjustment of age as a covariate, there was no statistically significant difference in the concentration of any cytokine between fibromyalgia and knee osteoarthritis patients. Conclusion: Patients with knee osteoarthritis and fibromyalgia with the same duration and intensity of pain demonstrate similar concentrations of cytokines. Aging may play a role in cytokine profile, a finding not so extensively addressed in the literature and one that should be further investigated.
Palavras-chave
cytokines, osteoarthritis, fibromyalgia, aging
Referências
  1. Alkan BM, 2014, MOD RHEUMATOL, V24, P166, DOI 10.3109/14397595.2013.854046
  2. ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816
  3. Ang DC, 2011, PAIN MED, V12, P1154, DOI 10.1111/j.1526-4637.2011.01179.x
  4. Bazzichi L, 2007, CLIN EXP RHEUMATOL, V25, P225
  5. Centers for Disease Control and Prevention, 2012, FIBR
  6. Chapman RS, 1990, MANAGEMENT PAIN, P580
  7. Curfs JHAJ, 1997, CLIN MICROBIOL REV, V10, P742
  8. Diatchenko L, 2006, PAIN, V123, P226, DOI 10.1016/j.pain.2006.04.015
  9. Ferraro KF, 1999, J GERONTOL B-PSYCHOL, V54, pS339
  10. Ferrero-Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365-2249.2006.03261.x
  11. Ferrucci L, 2002, J AM GERIATR SOC, V50, P1947, DOI 10.1046/j.1532-5415.2002.50605.x
  12. FORSETH KO, 1992, SCAND J RHEUMATOL, V21, P74
  13. Gur A, 2002, J RHEUMATOL, V29, P358
  14. Hassett AL, 2012, J PAIN, V13, P959, DOI 10.1016/j.jpain.2012.07.003
  15. Helmark IC, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3064
  16. Iannone F, 2010, CURR DRUG TARGETS, V11, P586
  17. Kirkwood BR, 2006, ESSENTIAL MED STAT
  18. Kotlarz H, 2009, ARTHRITIS RHEUM, V60, P3546, DOI 10.1002/art.24984
  19. Levinger I, 2011, ARTHRITIS RHEUM-US, V63, P1343, DOI 10.1002/art.30287
  20. Livshits G, 2009, ARTHRITIS RHEUM, V60, P2037, DOI 10.1002/art.24598
  21. Maddali Bongi S, 2010, REUMATISMO, V62, P4
  22. Menzies V, 2010, BIOL RES NURS, V11, P387, DOI 10.1177/1099800409348328
  23. Miller GD, 2008, J AM GERIATR SOC, V56, P644, DOI 10.1111/j.1532-5415.2007.01636.x
  24. Mobily PR, 1994, J AGING HEALTH, V6, P139, DOI 10.1177/089826439400600201
  25. Ortega E, 2009, EXERC IMMUNOL REV, V15, P42
  26. Peake J, 2010, AM J PHYSIOL-REG I, V298, pR1485, DOI 10.1152/ajpregu.00467.2009
  27. Pelletier JP, 2001, ARTHRITIS RHEUM, V44, P1237, DOI 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F
  28. Penninx BWJH, 2004, J RHEUMATOL, V31, P2027
  29. Pongratz DE, 2000, SCAND J RHEUMATOL, V29, P3
  30. Ravaud P, 1996, BRIT J RHEUMATOL, V35, P761
  31. Russel IJ, 2001, BONICAS MANAGEMENT P, P543
  32. Salemi S, 2003, J RHEUMATOL, V30, P146
  33. Saxne T, 2003, RHEUMATOLOGY, V42, P903, DOI 10.1093/rheumatology/keg214
  34. Staud R, 2011, BEST PRACT RES CL RH, V25, P155, DOI 10.1016/j.berh.2010.01.010
  35. Staud R, 2007, EXPERT OPIN PHARMACO, V8, P1629, DOI 10.1517/14656566.8.11.1629
  36. Togo F, 2009, EXP BIOL MED, V234, P232, DOI 10.3181/0808-RM-254
  37. Uceyler N, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-245
  38. Wallace DJ, 2006, CURR PHARM DESIGN, V12, P17, DOI 10.2174/138161206775193208
  39. Wallace DJ, 2001, RHEUMATOLOGY, V40, P743, DOI 10.1093/rheumatology/40.7.743
  40. Wang H, 2009, CLIN J PAIN, V25, P1, DOI 10.1097/AJP.0b013e31817e13a3
  41. WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203
  42. World Health Organization, 1995, PHYS STAT US INT ANT